AzTrials
AzTrials

Malnourished Children With Watery DiarrhoeaPhase 2NCT01821586

Modified ORS Solution for Severely Malnourished Children

A Phase 2 study testing Modified ORS-1, Modified ORS-2 (ReSoMal) and Modified ORS-3 (Benefibre) in people with Malnourished Children With Watery Diarrhoea, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Diarrhoea and malnutrition are the common childhood illnesses responsible for higher deaths in developing counties. Physiologically, malnourished children excrete lower amounts of salts and water in diarrhoeal stools, and they also are unable to handle excessive salts and water load. Read more about this study

Who is it for?
Ages 6 to 36 months
What is being tested?
Modified ORS-1, Modified ORS-2 (ReSoMal) and Modified ORS-3 (Benefibre)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
189 participants
Where
1 siteBangladesh
Study dates
Apr 2006to Jul 2009
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 36 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Some or severe dehydration (assessed by WHO Guidelines).
  • Weight for height (W/H) <70% of NCHS median or with bipedal edema.
  • Written informed consent from parents/ guardians

Who cannot join

  • Blood or mucus in stools
  • Have received antidiarhoeal drugs for their diarrhoea
  • Severe diseases (e.g. severe pneumonia with respiratory distress, clinical sepsis, meningitis) requiring intensive care and other ancillary support like O2 inhalation, oropharyngeal suction etc.

Trial locations and contacts

1 site in 1 country.

Bangladesh1 site
  • Dhaka Hospital, icddr,b

    Dhaka, 1212

Other trials in Bangladesh

About this study

Official title: Optimisation of Oral Rehydration Solution and Evaluation of the Efficacy of Benefiber(Partially Hydrolyzed Guar Gum) Containing Modified Oral Rehydration Solution in the Treatment of Severely Malnourished Children With Watery Diarrhoea

Diarrhoea and malnutrition are the common childhood illnesses responsible for higher deaths in developing counties. Physiologically, malnourished children excrete lower amounts of salts and water in diarrhoeal stools, and they also are unable to handle excessive salts and water load. Some times they are found to be hyponatraemic due to the shift of sodium inside the cells (inefficient Na+ /K+ pump), and fluids containing higher amounts of sodium (such as the standard ORS) may lead to further increase in the intracellular sodium, fluid overload and heart failure. They also have depleted in potassium stores in the body. Recently, the WHO recommended a special ORS formulation, known as ReSoMal, for management of diarrhoea in severely malnourished children that contains a lower amount of sodium (45mmol/L) and higher amount of potassium (40 mmol/L) than the standard WHO-ORS. It is felt that an ORS containing lower sodium and higher potassium concentration may be useful in correcting hypokalemia, and in lowering the risks of excess sodium and /or overhydration, in severely malnourished children with diarrhoea. The safety of ReSoMaL is, however, still in question due to the risk of hyponatraemia, including symptomatic hyponatraemia, especially in the treatment of severe watery diarrhoea due to Vibrio cholerae and ETEC where loss of sodium in the stool exceeds than that is contained in ReSoMal. Thus an ORS solution with modest concentration of sodium (75 mmol/L) and higher concentration of potassium (40 mmol/L) have been suggested for the treatment of diarrhoea in these children. To improve the efficacy of oral rehydration, in terms of reducing the severity of purging and diarrhoea duration, different approaches (changing the substrates/ reducing the sodium and glucose concentration and osmolarity) have been tried with limited success. Benefiber (partially hydrolysed guar gum), a soluble fiber if added to a ORS solution is expected to be fermented in the colon liberating short chain fatty acids (SCFAs). SCFAs stimulate sodium and water absorption from the colon, and they have trophic effect, act as a fuel source for the colonocytes, have antibacterial properties and stimulates the production commensal flora, thereby may enhance recovery from acute diarrhoea in severely malnourished children. The aims of our proposed study are to examine whether an ORS solution with a modest concentration of sodium will prevent the occurrence of hyponatraemia including symptomatic hyponatraemia, and also whether addition of benefiber will improve the efficacy of ORS solution. This will be a randomized, double blind, controlled clinical trial in 186 children with severe malnutrition and watery diarrhoea (62 in each of the three treatment groups) to compare the efficacy of (i) the currently recommended ORS with some modofication(Na+ 75 mmol/L and K40 momol/L and minerals-Zinc, copper and magnesium), (ii) ReSoMal (Na+ 45 mmol/L), (iii) Currently recommended ORS (Na+ 75 mmol/L, K 40 momol/L and added minerals) with added Benefiber (25 grams/L), in the treatment of acute watery diarrhoea in children with severe malnutrition

Read the detailed description

Study Design This will be a randomized, double-blind, controlled clinical trial to assess the efficacy of three different modified ORSs: (i) Currently recommended ORS with some modification (Na+ 75, K 40 mmol/L and added minerals); (ii) Resomal (Na+ 45); (iii) Currently recommended ORS (Na+ 75 , K 40 mmol/L and added minerals) with added benefiber (25 grams/L) in the treatment of acute watery diarrhoea in children with severe malnutrition.

STUDY POPULATION Children of either sex, aged 6 months to 3 years, presenting with acute watery diarrhoea of <7 days duration will be screened.

Sample Size

The sample size of this study has been determined based on the followings:

  1. Persistence of hyponatraemia: We anticipate that 10% of the children will remain hyponatraemic in the Modified ORS-1 treatment group compared to 30% children in the Modified ORS-2 (ReSoMal). Assuming 5% level of significance and 80% power, the sample size in each group is 60.
  2. Recovery from diarrhoea: In a recent clinical trial33 of ORS solution in severely malnourished children with acute watery diarrhoea, the mean +SD duration of diarrhoea was 66 (32) h. We anticipate that a 25% reduction in the diarrhoea duration in children receiving Benefiber-added ORS. Considering 5% level of significance and 80% power the required sample size in each group is 59.
  3. Anticipating a drop out of around 5% we need 62 children in each group. Randomization After enrolment into the study the patient will be randomized to receive one of the following three solutions:
  4. Case Management: Following the standardized protocol for management of severely malnourished children used at ICDDR,B hospital 20,23. 5.1 Fluid therapy (oral) Dehydration will be assessed according to the WHO guidelines, modified for in our last multicentre clinical trial of reduced osmolarity ORS in adult cholera and children with watery diarrhoea (17). In children with some dehydration, the fluid deficit will be corrected with the assigned ORS @ 10ml/kg/hr for the first two hours, then 5ml /kg/hr until the deficit will be corrected. In addition, on going stool looses will be replaced @ 5-10 ml/kg/hr after each watery stool. For high purging patient, the ORS intake will be adjusted according to the ongoing stool loss. ORS therapy will be continued until diarrhoea ceased. Children with severe dehydration, initial rehydration will be done with IV fluid(cholera saline) until the patient is out of shock or disappearance of signs of severe dehydration then the rest of the rehydration will be done as for rehydration in patients with some dehydration as described above. 5.2 Management of infection: Children without apparent extraintestinal infection will receive Inj ampicillin 100 mg/kg.24 h in 3 divided doses and Inj. Gentamicin @ 5ml/kg.24 h in 2 divided doses for 5 days. Children with lower respiratory tract infection will receive Inj. Ceftriaxone 75 mg /kg.day for 5 days, and those with cholera will receive syrup Azithromycin 20 mg/kg once within 20 minutes of randomization. 5.3 Diet: Mothers will be advised to continue breastfeeding. Supplementary feeding with milk suji (milk, rice powder mixture, energy 70 kcal/100ml) will be given 10 ml/Kg.feed two hourly for day 1 and increased slowly up to 150 Kcal/Kg.day over 7 days according to demand. If the child has poor appetite, or is weak, or has painful stomatitis or glossitis, food will be delivered through nasogastric tube until able to take food orally. Additionally, semisolid foods (Rice, lentil, vegetable etc.) will be given to older children during convalescent and rehabilitation phase. 5.4 Vitamin and Mineral Supplements Children older than one year without xeropthalmia will be given 200,000 units of vitamin A and those 6-12 months age will be given 100,000 units of vitamin A on admission. Children with xeropthalmia will receive the same dose on three occasions: on admission, on the following day, and at discharge. Folic acid 1.25 mg and elemental zinc 2 mg/kg will be given until discharge and some medicine will be supplied with the patient to continue upto 15 days. Children will also receive multivitamin drops (1 ml contains Vit A palmitate 5000 IU, vitamin D 1000 IU, thiamine hydrochloride 1.6 mg, riboflavin 1 mg, pyridoxine hydrochloride 1 mg, nicotinamide 10 mg, calcium D- pantothenate 5 mg, and ascorbic acid 50 mg) in a dose of 1 ml twice daily until discharge and some medicine will be supplied with the patient to continue upto 15 days (half the dose for infants, aged <1 year). Hypoglycemia (blood glucose <3.0 mmol/L) will be managed with 50 ml 10% glucose orally or by nasogastric tube. Inj 25% glucose 2 ml/kg will be given if the level of blood glucose below 1.5 mmol/L. Hyponatraemia (serum sodium <115 mmol/L with or without symptoms) will be managed with Inj. 3% NaCl 12 ml/kg I/V slowly over 4 hours.
  5. Measurements 6.1 Fluids intakes ( IV, ORS and water) every 6 hours IV fluid will be infused through a calibrated soluset, the amount infused will be noted every 6 hours if the patient is receiving; ORS will be supplied after measuring with a calibrated cylinder and the amount of intake will be noted every 6 hours, if any left over that will be deducted from previous offer. Water will also be measured in a similar way.

6.2 Output (stool, urine and vomit) every 6 hours. Stool will be collected in a bucket of known weight beneath the cholera cot with a central hole and measured every 6 hours with an electronic scale of a precision of 1g. Urine will be collected by pediatric urine collector bag and measured with a calibrated cylinder in ml. Vomit will be collected in a pre-weighed bowl and measured with an electronic scale 6.3 Food intake every 6 hours The children will be offered a defined food of known calorie after measuring with an electronic scale of precision of 1g. Any left over will be measured and subtracted from the amount offered and amount ingested will be recorded every 6 hours. The calorie intake will be estimated from the amount of diet the child consumed.

6.4 Nude body weight will be measured at admission, after rehydration and every 6 hours until recovery of diarrhoea and then at the end of every 24 hours and at discharge

Being tested
Modified ORS-1, Modified ORS-2 (ReSoMal), Modified ORS-3 (Benefibre)
Keywords
Diarrhoea;, Severe malnutrition;, Benefiber;, ReSoMal;, modified ORS
Medical subject headings
Diarrhea, Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Modified ORS-1Other

  • Modified ORS-2 (ReSoMal)Other

  • Modified ORS-3 (Benefibre)Other

Study groups in NCT01821586
Study groupRoleWhat they receive
Modified ORS-1ExperimentalModified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
Receives: Other: Modified ORS-1
Modified ORS-2 (ReSoMal)ExperimentalModified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
Receives: Other: Modified ORS-2 (ReSoMal)
Modified ORS-3 (Benefibre)ExperimentalModified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
Receives: Other: Modified ORS-3 (Benefibre)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stool weight

    Collection of stool in cholera cot and measured every 6 hours with a using a electronic scale

    Measured: up to 72 hours

Secondary outcomes (1)
  1. Duration of Diarrhoea

    Time from the onset of randomization upto the stopage of diarrhoea

    Measured: up to 72 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2013 (estimated)
  2. Study startApr 2006
  3. Primary completionJul 2009
  4. Study completionJul 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
189 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01821586
Sponsor's protocol ID
2006-005
Status last verified
Jan 2006
First submitted
27 Mar 2013
Last updated
21 Dec 2016
Results posted
No
Data monitoring committee
Yes

Publications

  • Alam NH, Ashraf H, Kamruzzaman M, Ahmed T, Islam S, Olesen MK, Gyr N, Meier R. Efficacy of partially hydrolyzed guar gum (PHGG) supplemented modified oral rehydration solution in the treatment of severely malnourished children with watery diarrhoea: a randomised double-blind controlled trial. J Health Popul Nutr. 2015 May 1;34:3. doi: 10.1186/s41043-015-0003-3.

    PubMed 26825757

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Modified ORS-1, Modified ORS-2 (ReSoMal) and Modified ORS-3 (Benefibre) in people with Malnourished Children With Watery Diarrhoea, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stool weight (time frame: up to 72 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01821586, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in